Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms HZ-Q1070 |
Target |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Malignant Neoplasm | Phase 1 | CN | 25 Mar 2024 | |
B-Cell Malignant Neoplasm | Phase 1 | CN | 25 Mar 2024 | |
B-Cell Malignant Neoplasm | Phase 1 | CN | 25 Mar 2024 | |
Autoimmune Diseases | Phase 1 | CN | - | |
Hematologic Neoplasms | Phase 1 | CN | - | |
B-cell lymphoma recurrent | IND Approval | CN | 20 Nov 2023 | |
B-cell lymphoma recurrent | IND Approval | CN | 20 Nov 2023 | |
B-cell lymphoma recurrent | IND Approval | CN | 20 Nov 2023 | |
B-cell lymphoma refractory | IND Approval | CN | 20 Nov 2023 | |
B-cell lymphoma refractory | IND Approval | CN | 20 Nov 2023 |